

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/540,306	06/20/2005	Michael O'Rourke	084329-000000US	6397	
20350 TOWNSEND	7590 12/09/200 AND TOWNSEND AN		EXAM	UNER	
TWO EMBARCADERO CENTER			SCHILLINGER, ANN M		
EIGHTH FLO SAN FRANCI	OR SCO, CA 94111-3834		ART UNIT	ART UNIT PAPER NUMBER	
			3774		
			MAIL DATE	DET HERMANDE	
			MAILDATE	DELIVERY MODE	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/540,306 O'ROURKE ET AL. Office Action Summary Examiner Art Unit

			1		
	ANN SCHILLINGER	3774			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D/ - Extensions of time may be available under the provisions of 37 CFR 1.1: A William of Modern Committee and the provisions of 37 CFR 1.1: A William of Modern Committee and the provisions of 37 CFR 1.1: A William of Modern Committee and the provisions of 37 CFR 1.1: A William of Modern Committee and the provisions of 37 CFR 1.1: A William of Modern Committee and the provisions of 37 CFR 1.1: Any reply received by the Office later than three months after the mailing agented catent term adjustment, See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this o D (35 U.S.C. § 133).			
Status					
3) Since this application is in condition for allowar	action is non-final. nce except for formal matters, pro		e merits is		
closed in accordance with the practice under E	x parte Quayle, 1955 C.D. 11, 45	3 O.G. 213.			
Disposition of Claims					
4) Claim(s) 1-29 is/are pending in the application. 4a) Of the above claim(s) is/are withdrav 5) Claim(s) is/are allowed. 6) Claim(s) 1-29 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	wn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the I drawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	a 37 CFR 1.85(a). jected to. See 37 C			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document: 2. Certified copies of the priority document: 3. Copies of the certified copies of the priority document: 4 See the attached detailed Office action for a list.	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National	Stage		
Attachment(s)	6- <u>-</u>				
1) Notice of References Cited (PTO-892)	Interview Summary Paper No(s)/Mail Da				

3) Information Disclosure Statement(s) (FTO/SE/CE) Paper No(s)/Mail Date _____.

5) Notice of Informal Patent Application 6) Other: _____.

Art Unit: 3774

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 8-12, 14, 17, 18 are rejected under 35 U.S.C. 102(b) as being anticipated by Barefoot et al. (US Pat. No. 3,726,279). Barefoot et al. discloses the following of the claimed invention: a method of treating a stiffened blood vessel to help it resume normal function, said method comprising at least substantially encasing a stiffened portion of said blood vessel (col. 2, line 65 through col. 3, line 14) with an elastic membrane formed of biocompatible material (10) such that said membrane engages said stiffened portion of said blood vessel to thereby reduce the external diameter of said stiffened portion of said blood vessel. The opposing end portions of the membrane sheet may be secured by suturing (27) or with a clamp (30, Figure 9). Barefoot et al. also discloses that the membrane may be in the form of a spiral (please see Figure 6).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 2-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Barefoot et al. in view of Khanghani et al. (US Pat. No. 6,984,201). Barefoot et al. teaches the invention

Art Unit: 3774

the heart's bloodflow.

such as the ascending aorta. Khanghani et al. teaches a blood circulation device on the ascending aorta in col. 9, lines 8-29 for the purpose of properly maintaining the heart's bloodflow.

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to use the device of Barefoot et al. on the ascending aorta in order to properly maintain

substantially as claimed, however, Barefoot et al. does not teach placing the device on an artery

Claims 5, 6, 28, and 29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Barefoot et al. in view of Chuter (US Pat. No. 5,387,235). Barefoot et al. teaches the invention substantially as claimed, however, Barefoot et al. does not teach constructing the device from a graft of woven polyester. Chuter teaches a stent with a woven polyester graft in col. 9, lines 12-43 for the purpose of utilizing the material's elasticity. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of Barefoot et al. by constructing it from a graft of woven polyester in order to utilize the material's elasticity.

Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Barefoot et al. in view of Von Oepen (US Pub. No. 2002/0151959). Barefoot et al. teaches the invention substantially as claimed, however, Barefoot et al. does not teach dilating the vessel prior to treatment. Von Oepen teaches a stent where the vessel is dilated prior to treatment in paragraphs 0001-0002 for the purpose of preventing the vessel from closing. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the process of Barefoot et al. by dilating the vessel prior to treatment in order to prevent the vessel from closing.

Art Unit: 3774

Claim 13 is rejected under 35 U.S.C. 103(a) as being unpatentable over Barefoot et al. in view of Spaulding (US Pat. No. 5,304,200). Barefoot et al. teaches the invention substantially as claimed, however, Barefoot et al. does not teach welding the ends of the prosthesis. Spaulding teaches a stent with welded ends in col. 5, lines 13-49 for the purpose of securing the prosthesis in its desired shape. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of Barefoot et al. by welding the ends of the prosthesis in order to secure the prosthesis in its desired shape.

Claim 15 is rejected under 35 U.S.C. 103(a) as being unpatentable over Barefoot et al. in view of Jones (US Pat. No. 4,202,349). Barefoot et al. teaches the invention substantially as claimed, however, Barefoot et al. does not teach markings on the prosthesis. Jones teaches a stent with markings in col. 2, line 52 through col. 3, line 16 for the purpose of helping the physician to properly locate the prosthesis. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of Barefoot et al. by placing markings on the prosthesis in order to help the physician to properly locate the prosthesis.

Claim 16 is rejected under 35 U.S.C. 103(a) as being unpatentable over Barefoot et al. in view of Dusbabek et al. (US Pub. No. 2001/0007082). Barefoot et al. teaches the invention substantially as claimed, however, Barefoot et al. does not teach how the sheet membrane is formed. Dusbabek et al. teaches a stent where a cylinder is cut to form different structures to be used with the prosthesis in paragraphs 0074-0076 for the purpose of allowing the user to create the desired shape for the prosthesis. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of Barefoot et al. by using

Art Unit: 3774

a cut cylinder to form different structures to be used with the prosthesis in order to allow the user to create the desired shape for the prosthesis.

Claims 19-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Barefoot et al. Barefoot et al. teaches the invention substantially as claimed except for the specific properties of size, and stiffness claimed by the Applicant. It would have been obvious to one having ordinary skill in the art at the time the invention was made to construct the prosthesis with the claimed physical characteristics, since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art.

Claims 25 and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Barefoot et al. in view of Silverstrini et al. (US Pat. No. 4,834,755). Barefoot et al. teaches the invention substantially as claimed, however, Barefoot et al. does not teach using elastic polyurethane in the prosthesis. Silverstrini et al. teaches a biological prosthesis using elastic polyurethane in columns 5 and 6 for the purpose of utilizing the material's biocompatibility. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of Barefoot et al. by using elastic polyurethane in the prosthesis in order to utilize the material's biocompatibility.

Claim 27 is rejected under 35 U.S.C. 103(a) as being unpatentable over Barefoot et al. in view of Barath (US Pub. No. 2002/0116016). Barefoot et al. teaches the invention substantially as claimed, however, Barefoot et al. does not teach inserting the device thoracoscopically.

Barath teaches a vascular prosthesis that is inserted thoracoscopically in paragraphs 0027-0029 for the purpose of using the less-invasive closed-chest surgical methods. Therefore, it would

Art Unit: 3774

have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of Barefoot et al. by inserting the device thoracoscopically in order to use the less-invasive closed-chest surgical methods.

Response to Arguments

Applicant's arguments with respect to claims 1-29 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANN SCHILLINGER whose telephone number is (571)272-6652. The examiner can normally be reached on Mon. thru Fri. 9 a.m. to 4 p.m..

Art Unit: 3774

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Isabella can be reached on (571) 272-4749. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/A. S./ Examiner, Art Unit 3774 /William H. Matthews/ Primary Examiner, Art Unit 3774